Biopharma News

Mar 09, 2017
By BioPharm International Editors
The agency granted Pfizer, Cellectis, and Servier clearance to begin clinical development with UCART19.
Mar 09, 2017
Senator Chuck Grassley sent a letter to Kaléo questioning the drugs high listing price.
Mar 07, 2017
Premium pricing in the US produces excess revenue for pharma companies. According to a new assessment, only 66% of those excess funds go to R&D.
Mar 07, 2017
By BioPharm International Editors
The companies have entered into an agreement to develop and commercialize a mAb for the prevention of lower respiratory tract illness in young children.
Mar 07, 2017
By BioPharm International Editors
BeiGene and the Guangzhou Development District have established a joint venture to build a biologics manufacturing facility in China.
Feb 27, 2017
By BioPharm International Editors
Sanofi and Lonza formed a joint venture to build and operate a large-scale mammalian cell culture facility for monoclonal antibody production in Visp, Switzerland.
Feb 24, 2017
Sarepta sold the priority review voucher for Exondys 51, a controversial treatment for Duchenne Muscular Dystrophy, to Gilead.
Feb 22, 2017
By BioPharm International Editors
FDA granted inotuzumab ozogamicin priority review and accepted its BLA for filing.
Feb 21, 2017
The regulatory agency rejected the medication, citing various issues related to device use.
Feb 13, 2017
By BioPharm International Editors
The companies entered into a license agreement for Immunomedic’s antibody-drug conjugate sacituzumab govitecan.
native1_300x100
lorem ipsum